Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

Journal of Medicinal Chemistry

Volumn 50, Issue 18, 2007, Pages 4453-4470

  Hasegawa, Masaichi ^a   Nishigaki, Naohiko ^a   Washio, Yoshiaki ^a   Kano, Kazuya ^a   Harris, Philip A ^a   Sato, Hideyuki ^a   Mori, Ichiro ^a   West, Rob I ^a   Shibahara, Megumi ^a   Toyoda, Hiroko ^a   Wang, Liping ^b   Nolte, Robert T ^b   Veal, James M ^b,c   Cheung, Mui ^b  

^a Development and Medical Affairs Division   (Japan)

^b GLAXOSMITHKLINE   (United States)

^c Serenex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; NITROGEN; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UREA; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; DRUG BINDING; DRUG POTENCY; ENZYME ACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZIMIDAZOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NIH 3T3 CELLS; PHOSPHORYLATION; RECEPTOR, TIE-2; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34548489855     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0611051     Document Type: Article

References (31)

1. (a) Cherrington, J. M.; Strawn, L. M.; Shawver, L. K. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv. Cancer. Res. 2000, 79, 1-38.
2. (b) Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100, 2491-2499.
3. (a) Verheul, H. M.; Hoekman, K.; Jorna, A. S.; Smit, E. F.; Pinedo, H. M. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000, 5 (Suppl. 1), 45-50.
4. (b) Underiner, T. L.; Ruggeri, B.; Gingrich, D. E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 2004, 11, 731-745.
5. (a) Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60, 203-212.
6. (b) Shinkaruk, S.; Bayle, M.; Lain, G.; Deleris, G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3 (2), 95-117.
7. (a) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolò[3, 4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
8. (b) Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J. Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116-1119.
9. (c) Hennequin, L. F.; Stokes, S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
10. (d) Fiedler, W.; Serve, H.; Dohner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105 (3), 986-993.
11. (e) Ahmed, S. I.; Thomas, A. L.; Steward, W. P. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J. Chemother. 2004, 16 (Suppl. 4), 59-63.
12. (f) Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Rocher, J. P.; Shibahara, M.; Lie, W.; Sato, H.; Wang, L.; Nolte, R. T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 2005, 15 (9), 2203-2207.
13. Peters, K. G.; Kontos, C. D.; Lin, P. C.; Wong, A. L, Rao, P.; Huang, L.; Dewhirst, M. W.; Sankar, S. Functional significance of TIE-2 signaling in the adult vasculature. Recent Prog. Horm. Res. 2004, 59, 51-71.
14. Burchat, A. F.; Calderwood, D. J.; Friedman, M. M.; Hirst, G. C.; Li, B.; Rafferty, P.; Ritter, K.; Skinner, B. S. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of LCK - A selectivity insight. Bioorg. Med. Chem. Lett. 2002, 12, 1687-1690.
15. Zhou, B. N.; Johnson, R. K.; Mattern, M. R.; Fisher, P. W.; Kingston, D. G. The first naturally occurring TIE-2 kinase inhibitor. Org. Lett. 2001, 3, 4047-4049.
16. Saaristo, A.; Karpanen, T.; Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19, 6122-6129.
17. Horton, J. Albendazole: A broad spectrum anthelmintic for treatment of individuals and populations. Curr. Opin. Infect. Dis. 2002, 15, 599-608.
18. (a) Dumas, J. Protein kinase inhibitors from the urea class. Curr. Opin. Drug Discovery Dev. 2002, 5, 718-727.
19. (b) Smith R. A.; Barbosa, J.; Blum, C. L.; Bobko, M. A.; Caringal, Y. V.; Dally, R.; Johnson, J. S.; Katz, M. E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Lowinger, T. B.; Lyons, J.; Marsh, V.; Rogers, D. H.; Swartz, S.; Walling, T.; Wild, H. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 2001, 11, 2775-2778.
20. (c) Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncologic mutation of B-RAF. Cell 2004, 116, 855-867.
21. (d) Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
22. (e) Kubo, K.; Ohyama, S.; Shimizu, T.; Takami, A.; Murooka, H.; Nishitoba, T.; Kato, S.; Yagi, M.; Kobayashi, Y.; Iinuma, N.; Isoe, T.; Nakamura, K.; Iijima, H.; Osawa, T.; Izawa, T. Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg. Med. Chem. 2003, 11, 5117-5133.
23. (f) Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl]urea (BIRB 796). J. Med. Chem. 2003, 46, 4676-4686.
24. Abuzar, S.; Rao, K. V. B.; Sharma, S.; Gupta, S.; Katiyar, J. C. Syntheses and anthelmintic activity of 2-substituted 5(6)-arylthio-and 5(6)-arylsulfonylbenzimidazoles. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1985, 24B, 178-181.
25. Nagarajan, K.; Hendi, S. B.; Goud, A. N.; Sen, H. G.; Deb, B. N. Quest for anthelmintic agents. Part II. Benzothiazole and benzotriazole carbamates and 2-benzazolyl vinyl ketones. Indian J. Pharm. Sci. 1986, 48, 85-88.
26. Nagano, T.; Itoh, M.; Matsumura, K. Preparation of certain derivatives of benzoxazole. J. Am. Chem. Soc. 1953, 75, 2770-2771.
27. Bochis, R. J.; Olen, L. E.; Waksmunski, F. S.; Mrozik, H.; Eskola, P.; Kulsa, P.; Wilks, G.; Taylor, J. E.; Egerton, J. R. Substituted imidazo[1,2-a]pyridine-2-carbamate anthelmintics. J. Med. Chem. 1981, 24, 1518-1521.
28. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C. C.; Vllafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis. Structure 1999, 7, 319.
29. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr., D: Biol. Crystallogr. 1994, 50, 760-763.
30. Jones, T. A.; Bergdoll, M.; Kjeldgaard, M. O: A macromolecule modeling environment. Crystallogr. Model. Methods Mol. Des., [Pap. Symp.] 1990, 189-199.
31. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P. Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921.